DRUG APPROVALS

October 14, 2022

New Dual Incretin Agonist for Type 2 Diabetes

This first-in-class, once-weekly injectable agent has demonstrated significant positive outcomes in reducing A1C and weight in clinical trials.

October 14, 2022

Review of Selected NMEs 2022

October 14, 2022

New Drug Review 2022

October 15, 2021

Review of Selected NMEs 2021

October 15, 2021

New Drug Review 2021

October 16, 2020

New Drug Review 2020

October 16, 2019

Review of Selected NMEs 2019

October 16, 2019

New Drug Review 2019